Impact Factor
2.55
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.77
570 total citations
h5-index
29
h5 depth signal
Cited share
24.1%
184 of 764
Total citations
570
Citation footprint
Metric signal
1.04
External metric anchor
Self-citation
3.2%
18 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
812
China
475
Italy
147
Canada
133
United Kingdom
116
Citing Fields of Research
Psychiatry
1,165
Psychiatry & Psychology
384
Neurosciences
228
Neurodevelopmental Disorders
171
Education & Pedagogy
142
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,065
Articles tracked across the journal lifetime
Indexed publication set
764
184 cited publications
Last 12 months
65
5.9 publications/month
Open access share
100.0%
65 OA publications in the last year
Leading citing country
United States
812 citing publications
Leading citing field
Psychiatry
1,165 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v8n1,Jan. 2003-
v8n1,Jan. 2003-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Psychiatry
Issuing & Sponsoring Bodies
Contributor
International Neuropsychiatric Assoc
Broad Categories
Neurology
Psychiatry
Psychiatry
Neurodevelopmental Disorders
Music
Psychiatry & Psychology
Education & Pedagogy
MeSH Descriptors
Central Nervous System Diseases
Mental Disorders
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1017/s1092852926101254
Open DOI
Pharmacotherapy for social anxiety disorder: An evidence-based treatment review
Social anxiety disorder (SAD) is a common and often chronic psychiatric illness characterized by persistent fear of social or performance situations and associated functional impairment and avoidance. Although multiple pharmacologic trea...
02
DOI 10.1017/s1092852926101205
Open DOI
Clinical outcomes following five-day accelerated intermittent theta burst stimulation for treatment-resistant depression in routine clinical practice: A prospective naturalistic cohort study
Objectives: Treatment-resistant depression (TRD) is a debilitating condition occurring in major depressive disorder (MDD) and bipolar II disorder (BP-II). Intermittent theta burst stimulation (iTBS) is an established neuromodulation appr...
03
DOI 10.1017/s1092852926101278
Open DOI
Merging art with science: the reflex hammer meets the algorithm
The neurological examination is a carefully choreographed sequence of observations and elicited responses that transforms clinical signs into meaningful data, providing the trainee with a framework for formulating a possible diagnosis. T...
04
DOI 10.1017/s1092852926101230
Open DOI
Characterizing eating behavioral phenotypes in mood disorders: A cross-sectional investigation
Background: Maladaptive eating behaviors in mood disorders are diverse and clinically relevant but have only been characterized into phenotypes based on theoretical evidence. The objective of the current study is to assess the prevalence...
05
DOI 10.1017/s1092852926101187
Open DOI
Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders
Intravenous ketamine is a rapid-acting intervention for treatment-resistant depression (TRD) in adults with major depressive disorder and bipolar disorder (BD). While efficacy is established, a comprehensive integration of clinical, neur...
06
DOI 10.1017/s1092852926101175
Open DOI
How many suspected adult ADHD cases actually receive the diagnosis? Related factors in an assessment-seeking sample
Objective: Adult ADHD assessments have increased sharply in recent years, yet the diagnostic yield and predictors of confirmed ADHD among assessment-seeking individuals remain insufficiently understood. This study aimed to examine the so...
07
DOI 10.1017/s1092852926101199
Open DOI
Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort ( n = 695)
Objective: To determine whether pharmacologic exposure is associated with differences in fibromyalgia neurobehavioral phenotypes and whether medication burden explains symptom variability within phenotypes. Methods: We analyzed a multisi...
08
DOI 10.1017/s1092852926101138
Open DOI
Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO™ study
Background/Objective: Once-daily INGREZZA® (valbenazine), a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved for tardive dyskinesia (TD) and Huntington’s chorea. KINECT-PRO™ (NCT05859698) is currently the only s...
09
DOI 10.1017/s1092852926101151
Open DOI
Spatial working memory across psychiatric disorders in young adults
Objective: Impairments in spatial working memory (SWM) have been observed in several disparate psychiatric conditions. The present study investigated how SWM varied across a range of psychiatric disorders in a large sample of young adult...
10
Bibliographical & Catalog Notes
Issues for <Apr. 2002-> have subtitle: International journal of neuropsychiatric medicine.
Title from cover.
Approved for 3.0 credit hours in category 2 of the Physician's Recognition Award of the American Medical Association.
Latest issue consulted: Vol. 7, no. 4 (Apr. 2002).
Also issued online.
Official journal of the International Neuropsychiatric Assoc., <Apr. 2002->